BioPharm Systems announced that it has launched a new solution which enables life sciences companies that use Oracle Clinical, Oracle's clinical data management system, to copy studies between Oracle Clinical environments.
The Oracle Clinical Study Copy Tool is a flexible application that can be used for tasks such as transferring clinical studies from one Oracle Clinical instance to another, archiving a global library or clinical studies, and refreshing patient data in a non-production environment.
"We originally developed this Oracle Clinical application for a company that needed to migrate their global library and clinical studies from an external Oracle Clinical instance to a BioPharm Systems hosted environment," said Michelle Engler, principal consultant, BioPharm Systems. "During the development of the solution, several other companies showed interest in its broad capabilities, so we decided to release it to the greater clinical trials community."
Pharmaceutical, biotechnology, and medical device companies, in addition to clinical research organizations and academic institutions who license the solution can choose to either employ it on their own or have BioPharm Systems service their specific needs. Although it has zero footprint in Oracle Clinical, the application's security is maintained via Oracle Clinical and its standard credential controls.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.